In the phase 3 RECITE trial, romiplostim significantly reduced chemotherapy dose modifications due to thrombocytopenia vs placebo in gastrointestinal cancers.
Back
Managing Chemotherapy-Induced Thrombocytopenia With Romiplostim in GI Malignancies
Managing Chemotherapy-Induced Thrombocytopenia With Romiplostim in GI Malignancies
Episodes
All
All
Gerald Soff, MD, discusses data from the phase 3 RECITE trial showing that romiplostim reduces chemotherapy dose modifications in patients with GI cancer.
Gerald Soff, MD, discusses how romiplostim could improve long-term outcomes in patients with GI cancer and thrombocytopenia by preserving relative dose intensity.
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
3
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
4
European Commission Approves Camizestrant Plus CDK4/6 Inhibition for Emergent ESR1-Mutated Advanced Breast Cancer
5